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Clinical trial results of peripheral B cell depletion indicate abnormal proinflammatory 
B cell properties, and particularly antibody-independent functions, contribute to relapsing 
MS disease activity. However, potential roles of B cells in progressive forms of disease 
continue to be debated. Prior work indicates that presence of B cells is fostered within 
the inflamed MS central nervous system (CNS) environment, and that B cell-rich immune 
cell collections may be present within the meninges of patients. A potential association 
is reported between such meningeal immune cell collections and the subpial pattern of 
cortical injury that is now considered important in progressive disease. Elucidating the 
characteristics of B cells that populate the MS CNS, how they traffic into the CNS and 
how they may contribute to progressive forms of the disease has become of considerable 
interest. Here, we will review characteristics of human B cells identified within distinct CNS 
subcompartments of patients with MS, including the cerebrospinal fluid, parenchymal 
lesions, and meninges, as well as the relationship between B cell populations identified in 
these subcompartments and the periphery. We will further describe the different barriers 
of the CNS and the possible mechanisms of migration of B cells across these barriers. 
Finally, we will consider the range of human B cell responses (including potential for 
antibody production, cytokine secretion, and antigen presentation) that may contribute 
to propagating inflammation and injury cascades thought to underlie MS progression.
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iNTRODUCTiON
Roles of B cells in central nervous system (CNS) inflammatory diseases have been investigated in 
patients and through elegant animal model studies. Here, we will focus on studies carried out in 
human, with animal work described in more detail elsewhere in this issue. B cell responses have 
long since been recognized in MS with variable degrees of evidence implicating them in both early/
TABLe 1 | Strength of evidence implicating B cells in early/relapsing and later/progressive MS.
early/relapsing MS Later/progressive MS
Clinical 
arguments
Anti-CD20 therapy robustly limits new focal inflammatory brain lesions 
and MS relapses (34–36)
Anti-CD20 therapy may limit worsening of disability in (post hoc) 
subgroup analysis of PPMS patients (younger patients; those exhibiting 
gadolinium enhancing lesions) (37)
PLEX may improve resolution of steroid refractory relapses (38)
Biological 
arguments
CSF OCB already present early in relapsing MS course in many patients; 
IgG levels (39) and presence of IgM OCBs have been associated with 
MS activity (39–41)
CSF OCB present in majority of patients later in MS course; some 
implication that their presence is associated with more aggressive or 
progressive course (39, 40)
Abnormal autoantibodies against MOG (27–30) and KIR4.1 (31, 32) reported in some patients with MS; clinical significance remains unclear
IgG transfer from MS patients can induce complement-mediated demyelination in animals (27, 42)
Dynamic exchange of B cell clones found in MS CNS and periphery, and 
evidence that activation/maturation may occur in the periphery (13, 43)
Shared B cell/PC clones within different CNS subcompartments 
including parenchymal lesions, CSF as well as meninges (10)
Pathological 
arguments
Common lesion type in pathologic classification of demyelinating lesions notable for deposition of immunoglobulin (Ig) and complement (8)
Antibodies and myelin fragments have been identified within phagocytic cells in MS lesions (6, 44)
Meningeal inflammation including presence of B cells, as well as subpial 
cortical demyelinating lesions can be features of early MS (9)
B cell-rich meningeal aggregates associated with subpial cortical lesions 
reported as more common in progressive forms of MS (10–12)
PLEX, plasma exchange; OCB, oligoclonal bands; MOG, myelin oligodendrocyte glycoprotein; PC, plasma cell.
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relapsing and later/progressive disease (Table 1). The abnormal 
presence of antibodies in the CNS continues to represent the 
most consistent immunodiagnostic feature in patients with MS. 
Cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCBs) 
are reported in the CSF of over 90% of MS patients throughout 
disease stages (1–5). Over the years, pathological implication of 
B cells has included the demonstration of antimyelin antibodies 
inside phagocytic cells within MS lesions (6, 7), the observation 
that the most common demyelinating lesion pattern (Pattern 
II) is characterized by prominent deposition of antibodies and 
complement (8), and the more recent descriptions of meningeal 
immune cell collections that can be B cell rich (9–12). The latter 
were first described in a proportion of patients with progressive 
forms of MS and subsequently also within meninges of patients 
considerably earlier in their disease course (9–12). Molecular 
analyses of the Immunoglobulin (Ig) variable gene region of B 
cells and plasma cells from active parenchymal lesions, the CSF, 
or meninges of MS patients have revealed the persistence of (pre-
sumably antigen driven) clonotypes that are shared between these 
three different CNS subcompartments (10, 13–18). Antibodies 
generated from clonally expanded plasma cells derived from the 
CSF of MS patients were capable of both binding human and 
mouse CNS tissue, and causing complement-mediated demy-
elination and astrocyte activation in spinal cord explants (19). 
In spite of the long-standing implication of clonally expanded B 
cell populations and abnormal antibodies in the MS CNS, the 
antigens recognized by these antibodies are still subject of debate 
and different targets have been suggested such as viruses, axoglial 
proteins, and glycolipids (20–25). The more recent work-deriving 
antibodies from CSF-expanded B cell clones of MS patients sug-
gest that they may preferentially target neurons and astrocytes 
(19, 26). The significance of serum antibodies to molecules, such 
as MOG and KIR4.1, also continues to be investigated (27–33).
The observation that B cell depletion with anti-CD20 mono-
clonal antibodies substantially limits new relapsing MS disease 
activity (34–36, 45, 46) has made it clear that B cells play important 
roles in the immune cascades underlying CNS inflammation 
and has reinvigorated research efforts to elucidate mechanisms 
underlying such B cell roles. Of interest in this regard, is the 
observation that while anti-CD20 therapy rapidly reduces new 
relapsing MS disease activity, the abnormalities in CSF antibody 
measures seem to persist in the face of the therapeutic benefit 
(47). This indicates that the therapeutic mechanisms of action 
by which B cell depletion limits new MS relapses reflect at least 
in part antibody-independent roles of B cells. Indeed, B cells are 
now recognized to have multiple functions that may contribute to 
MS pathogenesis, in addition to their capacity to differentiate into 
antibody-secreting cells (plasmablasts/plasma cells) (Figure 1). B 
cells can be highly efficient antigen-presenting cells (APC) to T 
cells when presenting antigens that they initially recognize with 
their surface B cell receptor (BCR) (48). In this context, Harp 
et al. reported that memory B cells in MS patients can efficiently 
present neuro-antigens to T cells (49, 50). Moreover, activated 
B cells can modulate the local inflammatory response of both 
T cells and myeloid cells through secretion of proinflammatory 
or anti-inflammatory cytokines (described in detail in Li et al., 
in this issue). Some B cells support proinflammatory functions 
of other cells through production of TNFα, IL-6, GM-CSF, and 
Lymphotoxin-alpha (51–55), while IL-10 and IL-35 producing 
B cells possess anti-inflammatory (regulatory) roles (53, 56–58). 
In MS, B cells seem to be abnormally polarized toward a more 
proinflammatory phenotype (54, 55, 59, 60), and defects in their 
regulatory function have also been suggested by some but not all 
authors (55, 59–62).
Anti-CD20 therapy has also been studied in Phase III trials 
of patients with primary progressive MS (PPMS). Treatment in 
the initial trial using rituximab, failed to limit disease progres-
sion though a benefit was suggested in the subgroup of younger 
patients, and those with evidence of focal inflammatory brain 
lesions (37). The follow-up ORATORIO study of anti-CD20 
(ocrelizumab) focused on younger patients who were closer 
to clinical PPMS disease-onset, and demonstrated a modest 
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FiGURe 1 | Potential MS-relevant B cell responses. (1) B cells can function as efficient antigen-presenting cells (APC) especially in context of cognate 
B cell:T cell interactions. This may activate pathogenic T cells that in turn contribute to disease propagation. (2) B cells and/or plasma cells have the potential to 
produce anti-inflammatory cytokines (such as IL-10 and IL-35) but also proinflammatory cytokines (IL-6, LTα, TNFα, and GM-CSF). A lack of balance involving 
over-propensity of B cells to produce proinflammatory cytokines and their deficient production of anti-inflammatory cytokines has been demonstrated in patients 
with MS. Such B cell responses within the CNS may contribute to propagating CNS-compartmentalized inflammation. (3) B cells can differentiate into plasmablasts 
and plasma cells, which can elaborate pathogenic autoantibodies (and possibly also cytokines). (4) Similar to their established roles in normal lymphoid architecture 
formation, B cells may release factors that contribute to the formation and/or maintenance of persisting immune cell aggregates in the meninges of MS patients.
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treatment benefit in limiting the rate of progression of neuro-
logical disability (63, 64). A number of factors may limit a more 
robust effect of peripheral B cell depletion on progressive MS 
biology. Meningeal immune cell aggregates in which B cells can 
be a prominent feature may not be as efficiently targeted by anti-
CD20 antibodies that only weakly penetrate the CNS. It is also 
possible that long-lived plasma cells (that do not express CD20) 
and the antibodies they generate may play a more important role 
in progressive forms of MS compared to relapsing MS. B cells 
are known to play important roles in the formation of normal 
lymphoid follicle architecture (65, 66). Observations of B cell-rich 
immune cell collections in the meninges of MS patients [some 
of which recapitulate lymphoid follicle-like features (9, 11, 12) 
and reviewed by Pikor and Gommerman, in this issue] raise the 
intriguing possibility that B cells contribute to the formation and/
or maintenance of such structures. In doing so, the B cells may 
contribute to propagation of inflammation within the MS CNS. 
Some or all of the diverse functions of B cells which are now 
thought to contribute to inflammatory responses in the periphery 
of MS patients may also be relevant within the CNS.
It now appears likely that functionally distinct B cells con-
tribute to the MS disease process through diverse mechanisms 
within the distinct disease compartments and throughout 
different stages of the disease. Peripheral proinflammatory 
B cells play an important role in relapsing disease mechanisms 
(see Li et  al., in this issue), whereas meningeal collections of 
B cells potentially participate in the maintenance and propaga-
tion of CNS-compartmentalized disease. This review will focus 
on studies that implicate human B cells within the CNS of MS 
patients. We will highlight available findings form human studies 
that (I) consider the sites and characteristics of B cells within 
the MS CNS subcompartments, including CSF, parenchyma, 
and meninges; (II) how B cells might get there (barriers/traffick-
ing); and (III) what they might do there (responses that may be 
relevant to CNS injury processes).
where Are B Cells within the MS CNS?
B cells, plasmablasts, and/or plasma cells have been described in 
several subcompartments of the CNS of patients with MS, includ-
ing the CSF, parenchyma, and meninges (Figure 2A). Emerging 
studies are adding to our understanding of the profiles of such 
cells as well as the relationship between such cells in the different 
CNS compartments.
Cerebrospinal Fluid B Cells in MS
Early studies investigating CSF cytology suggested that the 
number and the relationship of B cells to other CSF immune 
cells (principally monocytes) may be associated with MS disease 
severity and progression (67). In particular, a high ratio (pre-
dominance of B cells) was associated with more rapid disease 
progression, whereas a low ratio (predominance of monocytes) 
was found in patients with slower progression (67). Subsequent 
CD19+ CD3+ Plasma cells FDCs
Meningeal Immune cell 
collections
Deep white matter 
immune cell infiltrates 
B cells and plasmablasts
within CSF
Cervical lymph 
nodes
Spleen or peripheral 
lymphoid structure
?
?
A B
FiGURe 2 | B cells in different compartments and implication for MS disease activity. (A) Cells of the B cell lineage (including primarily memory B cells, 
plasmablasts, and plasma cells) are found to persist in the inflamed MS CNS and occupy multiple subcompartments. These include the cerebrospinal fluid (CSF), 
parenchymal white matter lesions, and collections of immune cells within the meninges, which can be B cell rich. Somatic mutation analysis has demonstrated that 
the same B cell clones may occupy all three CNS subcompartments. Exactly how and where such clones initially access the CNS and how they communicate 
across these CNS subcompartments remains largely unknown. (B) The traditional view has held that new MS disease activity is triggered by activation of immune 
cells in the periphery (possibly triggered by pathogen-associated molecules recognized by cross-reactive T cells; referred to as molecular mimicry) and subsequent 
trafficking of the activated cells into the CNS (green arrow). However, the demonstration that the CNS clearly has lymphatics that drain into cervical lymph nodes and 
evidence from somatic mutation analysis indicating bidirectional trafficking of B cells between the CNS and the periphery (with much of the activation and clonal 
expansion apparently occurring in the periphery) suggests that relapses may also be “invited” from within the CNS (blue arrows). This might occur if proinflammatory 
B cells exit the chronically inflamed CNS carrying CNS antigens, which they may then present to T cells in the draining cervical lymph nodes with subsequent 
trafficking of the activated T cells into the CNS.
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work demonstrated that CSF B cells in MS CSF are largely class-
switched IgD−IgM− memory B cells (68) and that the main B cell 
effector subset are short-lived plasmablasts (69, 70). Over the 
years, several groups carried out somatic hypermutation analysis 
of the variable region of the heavy chain immunoglobulin (Ig 
VH) in B cells obtained from CSF of MS patients in compari-
son to circulating blood B cells obtained from the patients at 
the same time (14–18). A consistent finding was that MS CSF 
harbored increased frequencies of clonally expanded B cells 
(with post-germinal center memory characteristics) compared 
to the blood. The mutations appeared to be highly concentrated 
within the CDR3 region, which has been taken to indicate an 
antigen-driven selection process of B cells accumulating in the 
CSF of patients. Presorting and amplifying the variable region 
of the IgG gene from both total CD19+ B cells and CD138+ 
plasma cell/plasmablasts purified from the CSF of MS patients 
revealed that both sorted subsets harbored somatically mutated 
expanded clones (71). The repertoire within the CD138+ subset 
was more restricted though little sequence overlap was observed 
between the CD19+ and CD138+ repertoires (71). More recently, 
analysis of genes for IgM-chains in CSF B cells of MS patients 
revealed extensive accumulation of somatic hypermutation and 
clonal expansion in IgM-producing B cells (72). Whether or not 
these cells initially trafficked into the CNS as naïve B cells, their 
coexpression of activation-induced cytidine deaminase (AID, 
an enzyme crucial for somatic hypermutation and class switch 
recombination of antibodies, that is normally expressed during 
activation of B cells in germinal centers) provides further support 
that the intrathecal milieu in patients with MS sustains accumula-
tion of germinal center-like experienced B cells that can produce 
both IgM and IgG antibodies. Additional elegant work examining 
both CSF B cell IgG-H and Ig-κ chains transcriptomes, as well 
as the oligoclonal Ig proteomes derived from the same CSF of 
patients with relapsing-remitting MS, showed a correspondence 
between CSF Ig proteomes and B cell Ig transcriptomes, provid-
ing the most direct evidence that expanded CSF B cell clones are 
responsible for producing the abnormal Ig that comprises the 
CSF OCB in MS patients (73).
Parenchymal B Cells in MS Brains
Most histopathologic studies of MS are based on autopsy tissues, 
which tend to be obtained relatively late in the disease course. 
When patients undergo biopsy earlier in the course of disease, 
such tissues may not be representative of typical MS pathology 
as biopsies tend to be done only when the lesion and/or clinical 
presentation are sufficiently atypical. Thus, available insights into 
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the distribution and magnitude of B cell infiltrates within the MS 
CNS (whether in the parenchyma or meninges) largely reflect 
longer-standing disease states. With respect to the parenchyma, 
studies have generally indicated that the classical deep white 
matter perivascular demyelinating lesions of MS typically exhibit 
relatively few B cells and plasma cells compared to the greater 
abundance of myeloid cells and T cells (8, 74, 75). At the same 
time, demyelinating lesion classification has identified “Type II” 
lesions (that exhibit considerable Ig and complement deposi-
tion) as the most common demyelinating lesion type in MS (8, 
74). It is noteworthy that in a study of 26 active lesions from 11 
patients diagnosed with relatively early MS, demyelinated lesions 
reportedly exhibited considerable numbers of B cells as well as 
IgG-positive plasma cells, in addition to T cells and myeloid cells 
(75, 76). This raises the possibility that B cells and plasma cells 
may be a more common feature of early, as compared to later, 
MS parenchymal lesions. Somatic mutation analysis of B cells and 
plasma cells isolated from both parenchymal lesions and CSF of 
the same MS patients at autopsy demonstrated clonally expanded 
and somatically hypermutated populations within the tissue sam-
ples, as well as shared clones populating the tissue and CSF (77). 
Shared clones were subsequently demonstrated in parenchyma 
and meninges of the patients (10). These observations point to 
relatedness of expanded B cell and plasma cell clones in both 
parenchymal and extraparenchymal subcompartments of the MS 
CNS, at least later in disease.
B Cells Within Meningeal Immune Cell Collections  
in MS
Cellular immune aggregates have been reported in the meninges 
of patients with MS, some of which were found to be rich in B 
cells, and have been referred to as “ectopic follicles” or “follicle-
like structures” based on their resemblance to tertiary lymphoid 
tissues (TLT) (11, 12). Early studies described these structures 
mainly in subsets of relatively late-phase SPMS and PPMS 
patients (11, 12, 78, 79). Presence of these meningeal immune cell 
collections was associated with more aggressive clinical disease 
and a greater extent of tissue injury in the subjacent cortical 
regions. The pattern of the demyelinating subpial cortical injury 
associated with meningeal inflammation involved a gradient of 
microglial activation, reduced numbers of oligodendrocytes, 
and neuronal loss, such that the most severe injury was present 
in the most superficial cortical layers. Meningeal immune cell 
aggregates were most commonly found in the deep sulci of the 
temporal, cingulate, insula, and frontal cortex (79). Based on 
these initial reports, the prevailing concept was that meningeal 
inflammation in MS is a feature of a subset of patients with late/
progressive disease. However, recent imaging studies demonstrate 
leptomeningeal contrast enhancement in the brain of individuals 
with RRMS (80) and substantial meningeal inflammation has 
also been described in biopsy material obtained from patients 
relatively early in their MS disease course (9). While these biop-
sies were obtained for diagnostic purposes of atypical deep white 
matter lesions, the biopsy trajectories captured meningeal and 
cortical tissue that exhibited the typical features of cortical MS 
injury, and demonstrated considerable meningeal inflammation. 
The cortical tissue underlying the meningeal immune cell col-
lections in these early cases depicted a similar demyelinating 
injury pattern (with enhanced microglial activation, reduced 
number of oligodendrocytes, and neuronal/neuritic loss) as was 
described in the more chronic cases (11, 78). Further charac-
terization of meningeal immune cell aggregates in MS indicated 
that at least some are enriched in proliferating (Ki67+) CD20+ 
B cells. Presence of some plasma cells/plasmablasts, CD8+ and 
CD4+ T cells, and CXCL13-producing CD35+ cells with fol-
licular dendritic cell characteristics were also described (12, 
79, 81). As noted, somatic hypermutation analysis of the BCR 
in B cells and plasma cells isolated from meningeal immune 
cell aggregates, as well as parenchymal lesions and CSF from 
the same MS patients, demonstrated that related B cell clones 
populate all three compartments (10), again underscoring the 
relatedness of clonally expanded B cells found in the MS CNS. 
CNS-infiltrating B cells are also clonally related to peripheral B 
cells (13, 14, 18) raising intriguing questions about the dynamics 
involved in trafficking of B cells into the CNS and among these 
distinct CNS subcompartments as discussed below. It is still not 
clear whether formation of meningeal immune cell collections 
occurs commonly and throughout the different (early and late) 
phases of disease, and whether their presence contributes to, or 
is merely the consequence of underlying tissue injury. Indeed, 
some groups did not identify the presence of meningeal immune 
cell aggregates or a relation between such aggregates and corti-
cal injury (82). These discrepancies may reflect true biological 
heterogeneity across patients, transient presence of meningeal 
inflammation (for example, during periods of more active CNS 
inflammation), or technical reasons as these structures tend to be 
very small (≤100 μm in thickness) and may be lost depending on 
the approach to tissue processing.
what Routes Might B Cells Use to 
infiltrate the CNS?
Anatomical Routes to Cross the Blood/CNS Barriers
The CNS (comprising the brain and spinal cord) which was 
historically referred to as immune privileged is now referred to 
as immune specialized with the understanding that peripherally 
derived immune cells do patrol the CNS as part of normal physi-
ologic immune surveillance (83–85). This immune specialization 
is conferred by the presence of barriers that restrict the passage 
of large molecules and limit broader cell infiltration. While the 
most known of these specialized barriers is the blood–brain bar-
rier (BBB), two less well studied but nonetheless important other 
barriers are the blood–meningeal barrier (BMB) and the blood 
CSF barrier (BCB).
The Blood–Brain Barrier
The BBB is a structure formed by specialized endothelial cells 
(ECs) that separates the CNS from systemic circulation. CNS 
blood vessels are made of two main cell types: the ECs themselves 
and the mural cells that sit on the abluminal surface of the EC 
layer (i.e., pericytes and astrocytes). CNS ECs are characterized 
by the presence of tight junctions that limit the paracellular flux 
of solutes and by a very low rate of transcytosis. These properties 
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permit a tight control of the exchange between the brain and 
the blood (86). Maintenance of the BBB is governed by both 
cellular and non-cellular elements that interact with the ECs. 
Astrocytes, pericytes, and the extracellular matrix together 
provide structural and functional support to the BBB (87–89). 
The term “neurovascular unit” (NVU) additionally refers to 
neurons and microglia cells that also contribute to this barrier. 
At the level of the postcapillary venule, two distinct basement 
membranes (endothelial and parenchymal) define the inner and 
outer border of the perivascular space. Basement membranes 
keep members of the NVU in place and regulate their intercel-
lular cross-talk.
The Blood–Meningeal Barrier
The meninges are composed of three layers that surround 
the CNS (Dura mater, Arachnoid mater, and Pia mater) and 
contain the CSF located within the subarachnoid space. In 
the brain, the gray matter is directly adjacent to the menin-
ges. While the meninges were initially considered as a mere 
physical barrier preventing entry of infections and toxins into 
the CNS, more recent findings have established this tissue as 
a site of active immunity in both health and disease (84, 85, 
90). Similar to barrier membranes in the gut and lungs, the 
meninges can house a wide variety of immune-competent 
cells such as macrophages, dendritic cells, mast cells, innate 
lymphoid cells, and fibroblasts that can provide effective pro-
tection against microbes (91–93). As is the case with the other 
immunologically competent barriers, the meninges can also 
be the site of chronic inflammation in pathologic states. The 
description of meningeal immune cell collections associated 
with MS has reinforced the concept that the BMB could be an 
important pathway in immune cell CNS trafficking. Indeed, 
live imaging studies in animals demonstrate that lymphocytes 
cross the BMB prior to onset of CNS inflammation and appear 
to become reactivated in the subarachnoid space as part of 
disease instigation (94, 95). Relatively, little is known about the 
properties of ECs located in the meninges, which appear to dif-
fer in important ways from parenchymal ECs associated with 
the BBB. For example, meningeal microvessels lack the rich 
astrocytic ensheathment, which characterizes the microvessels 
in the CNS parenchyma (96).
The Blood CSF Barrier
Another port of entry into the CNS is the choroid plexus 
(CP) forming a barrier between the blood and CSF. This vil-
lous structure extends into the ventricular organs and is also 
responsible for producing the CSF. The CP is made up of a layer 
of epithelial cells surrounding a core of fenestrated capillaries 
and connective tissue, allowing the free diffusion of solutes from 
the blood toward the parenchyma through inter-endothelial 
gaps. The monolayer of epithelial cells has tight gap junctions 
that prevent the flux of macromolecules and cells and acts as 
a blood:CSF barrier (97). It has been shown that ICAM-1 and 
VCAM-1 are constitutively expressed by CP epithelial cells 
(98), and this barrier may be a port of entry of pathogenic 
TH17 cells during the commonly used animal model of CNS 
inflammation, experimental autoimmune encephalomyelitis 
(EAE), an influx mediated at least in part via CCR6/CCL20 
interactions (99).
Molecular Mechanisms Underlying Cell Trafficking 
into the CNS
The Multistep Process of Leukocyte Extravasation
In healthy individuals, there is a very low rate of ongoing immune 
surveillance of the CNS. Immune cell migration across barriers 
is normally tightly regulated and involves a multistep process. 
These different steps include rolling, firm adhesion, crawling, 
and extravasation (97, 100–104). The initial contact between 
leukocytes and the endothelium is usually mediated by adhesion 
molecules of the selectin family. This first step allows the reduc-
tion of the leukocyte velocity in the bloodstream, hence allowing 
them to detect the chemokine factors secreted by, or bound to 
ECs. The binding of chemokines to their cognate receptors 
expressed on the surface of leukocytes leads to an increased avid-
ity/affinity of interaction between cellular adhesion molecules 
(immunoglobulin family members such as VCAM1, ICAM1, 
ALCAM, and MCAM) and adhesion molecule receptors such as 
those of the integrin family, which contributes to firm adhesion of 
the cells to the endothelium. Subsequent leukocyte polarization 
and crawling (typically against the direction of blood flow) to sites 
permissive for diapedesis, requires the expression of ICAM1 and 
2 (but not VCAM1) by ECs and is a prerequisite for immune cell 
diapedesis across the BBB (94).
Leukocytes can then migrate through inter-endothelial 
regions (diapedesis) or directly through the ECs themselves. 
Expression of several of these adhesion molecules has been 
found to be highly increased in MS tissue and is thought to 
contribute to the extravasation of leukocytes into the CNS 
parenchyma of patients (100–106). Different preferential 
pathways and molecular mechanisms of trafficking across the 
BBB have already been identified for T cells and monocytes [for 
review, see Ref. (97)]. Less is known concerning B cell migration 
into the CNS.
Molecules Implicated in B Cell Migration into the CNS
Natalizumab, which binds VLA-4, is one of the most potent 
therapies in RRMS. Studies have mainly focused on its impact 
on T  cells migration across the BBB, but B cells express also 
high levels of VLA-4 (107, 108). A major role of VLA-4 in B 
cells migration across human adult brain-derived ECs has been 
shown in vitro, with a prominent role also identified for ICAM-1 
(108). A recent study has reported that the selective inhibition 
of VLA-4 expression on B cells reduces the susceptibility to EAE 
by decreasing B  cell accumulation inside the CNS but also by 
interfering with TH17/macrophage recruitment (109). Finally, 
another adhesion molecule named ALCAM (activated leukocyte 
cell adhesion molecule) seems to promote B cell trafficking into 
the CNS across the BBB (103). Nonetheless, little is known about 
whether distinct B cell subsets that have been implicated in MS 
utilize particular molecular pathways to get across the BBB, and 
whether and how B cells traffic across the other CNS barriers 
(BMB and CP), are among key questions that have not yet been 
elucidated.
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Dynamics of B Cell Infiltration into the MS CNS
Until recently, the documentation of clonally expanded B cells 
in the MS CNS including CSF, lesions, and meninges, has been 
taken as evidence that B cell clonal expansion is driven (by one 
or more unknown antigens) within the CNS of patients (10, 
13–18). More recent evidence points to the potential for more 
dynamic, bidirectional exchange of B cells between the CNS 
and periphery (Figure  2B), including clonal expansion that 
occurs in both compartments (13, 14). Since the initial study 
implicating active diversification of B cells on both sides of the 
BBB (18), two additional complementary studies confirmed that 
particular B cells found outside the CNS (in both peripheral 
blood and draining cervical lymph nodes), share clonality with 
B cells populating the brain (13, 14) and exhibit evidence of 
presumably antigen-driven expansion on both sides of the BBB. 
In one of these studies, using paired CNS tissue and draining 
cervical lymph nodes from the same patient source, not only 
were shared B cell clones identified in the two compartments, 
but the founding clones and much of the subsequent maturation 
involved in the bidirectional exchange, appeared to take place 
in the cervical lymph nodes rather than the CNS (13, 14). This 
could provide a mechanism for “epitope spread,” a phenomenon 
well described in animal studies whereby the antigenic target of 
the CNS inflammatory attack shifts over time as injury exposes 
additional epitopes (110). Supporting a role for B cells in such 
“epitope spread” in patients with MS are observations from 
antigen array studies indicating that the circulating repertoire of 
serum anti-CNS antibodies appears to expand in children with 
MS, yet constrict in children with monophasic CNS inflamma-
tory disease, over time (111).
It is now also apparent that the CNS is not as “immune privi-
leged” as previously thought, with organized lymphatic drain-
ing that allows CNS antigens and potential APC to exit from 
the CNS including the meninges and to access the  periphery 
(84, 85). Based on these observations, one can challenge the 
prevailing view that MS relapses are invariably triggered by 
some external stimulus (e.g., pathogen exposure) resulting 
in peripheral immune cell activation and trafficking into the 
CNS. Instead, cells capable of antigen presentation, such as B 
cells, may drain from the CNS into the draining lymph nodes, 
and present CNS antigens to T cells with subsequent T cell 
activation and trafficking involved in new relapsing disease 
activity.
How Might B Cells within the CNS 
Contribute to MS Disease Mechanisms?
While the capacity of B cells to mediate aberrant T cell activa-
tion in the periphery could explain the substantial contribu-
tion of B cells to relapsing MS biology (evidenced by robust 
relapse-reduction following B cell depletion with anti-CD20 
therapy), whether and how B cells may also contribute to 
progressive (non-relapsing) disease remains to be elucidated. 
The biology underlying CNS injury in progressive MS is now 
thought to involve a combination of degeneration and ongoing 
inflammation that is compartmentalized within the CNS (112). 
Such compartmentalized inflammation involves astrocyte and 
microglial activation, though the molecular mechanisms driv-
ing such chronic activation remain largely unknown. Since B 
cells are recognized to persist in the chronically inflamed MS 
CNS (10, 13, 14, 16), and evidence has mounted that B cells of 
patients with MS exhibit abnormal proinflammatory response 
profiles (54, 55, 59, 60), it has been tempting to consider 
whether B cells chronically residing in the CNS may contribute 
to propagating local injury processes even independent of B 
cell roles in relapsing disease biology. This concept is reinforced 
by reports of meningeal immune cell infiltrates which can be 
rich in B cells and that have now been identified in both early 
and late (9, 11, 12, 79) stages of MS. One potential mechanism 
by which B cells could contribute to ongoing injury is through 
secretion of CNS-directed autoantibodies (5, 6, 8). As noted, 
somatic mutation analysis has indicated that clonally expanded 
B cells and plasma cells are shared between the different CNS 
subcompartments (CSF, parenchyma, and meninges) (10). 
Moreover, CSF-derived B cell clones can produce antibody that 
binds CNS cells (including neurons and astrocytes) and can be 
shown to cause complement-mediated injury to such structures 
in CNS explants (19, 26). Antibody-independent contributions 
(e.g., Figure  1) of B cells to propagating inflammation in the 
MS CNS should also be considered. The great majority of B 
cells identified in the MS CNS (regardless of subcompartment) 
appear to be preferentially memory rather than naïve B cells 
(14, 15), and it is now recognized that memory B cells of MS 
patients may have particular proinflammatory propensities 
including the capacity to express exaggerated levels of immune 
activating molecules and proinflammatory cytokines (55, 59). 
This may be particularly relevant when considering meningeal 
B cell-rich immune collections and the subpial cortical demy-
elinating injury, which is now thought to importantly contribute 
to progressive loss of neurological function in patients with MS. 
These subpial demyelinating lesions are notable for microglial 
activation, astrogliosis, and neuronal loss, and their location 
may be associated with regions subjacent to areas of menin-
geal immune cell collections (81). It is intriguing to speculate 
whether particular B cell subsets persisting within such immune 
cell collections may impact the underlying glial neural cells 
through the release of specific soluble factors. In turn, what fac-
tors within the inflamed CNS milieu may sustain B cells in that 
environment? Does CNS persistence of particular B cell clones 
relate to the antigenic specificity of the B cells? In the case of 
primary CNS lymphoma, there is some evidence that specific 
recognition by tumoral B cells of CNS antigens contribute to 
fostering local tumor survival and proliferation (113), and such 
a mechanism may also contribute to persistence of B cells in the 
MS CNS. A number of features of the inflamed MS CNS may 
support B cells unrelated to their antigenic specificity. These 
include soluble factors known to support B cell survival that 
are produced by activated astrocytes and microglia  –  such as 
BAFF, IL-6, IL-10, and IL-15 – all reportedly found at increased 
levels within the CSF of MS patients (114–116). Some of these 
factors (BAFF and IL-6) also support the survival of plasma 
cells. In the context of EAE, plasmablasts and plasma cells have 
been implicated in regulating neuroinflammation through their 
production of cytokines such as IL-10 and IL-35, although it is 
BOX 1 | B cells in the MS CNS: what remains to be elucidated?
What are preferential routes of migration of B cells into the CNS?
Which molecules are involved in migration of distinct B cell subsets?
What are the molecular mechanisms that favor B cell persistence in the MS 
CNS?
What are the antigenic specificities of abnormal CSF immunoglobulins (Ig) in MS?
Which Ig are disease-relevant vs. an epiphenomenon of chronic activation?
Which response profiles (proinflammatory/anti-inflammatory) characterize CNS 
B cells?
What are the different roles of B cells within immune cell aggregates in the 
meninges?
What are the interactions between B cells and other cells in the inflamed MS 
CNS?
•	 Do they have direct effects on oligodendrocytes and neurons?
•	 Do they present antigen/s to T cells? Do they modulate T cell activation/
polarization?
•	 Do they influence astrocyte/microglia activation/polarization and 
vice versa?
December 2015 | Volume 6 | Article 6368
Michel et al. B Cells in MS CNS
Frontiers in Immunology | www.frontiersin.org
unclear if this is occurring exclusively in the periphery (lymph 
nodes) or also in the CNS itself (56, 117). Thus, identifying the 
particular B cell subsets that preferentially migrate into, and are 
then fostered within, the MS CNS, and elucidating how they 
may contribute to propagating local injury responses are of 
considerable interest for future studies.
Perspectives
The success of anti-CD20 therapies has made it clear that 
B cells contribute substantially to the initiation of MS relapses. 
Growing evidence suggests this largely reflects non-antibody-
dependent proinflammatory roles of B cells in the periphery, 
where they can aberrantly activate disease-relevant T cells, 
which in turn traffic to the CNS and mediate relapses. The 
inflamed MS CNS appears to foster persistence of B cells and 
plasma cells and the same clonally expanded populations 
can be found within different CNS subcompartments (CSF, 
parenchyma, and meninges). There is an early appreciation that 
multiple distinct barriers separate the CNS from the periphery, 
including the BBB, meningeal, and choroidal interfaces. Elegant 
studies now underscore the bidirectional trafficking of B cells 
between the CNS and the periphery and reveal that maturation 
of expanded clones that populate the CNS of patients may be 
peripherally rather than centrally driven. Despite key advances, 
little is known about B cell contributions to the chronic non-
relapsing CNS-compartmentalized inflammation that may 
underlie progressive tissue injury and worsening of disability 
in MS. A number of observations make such contributions 
(through both antibody-dependent and antibody-independent 
mechanisms) plausible and worthy of further study. Key obser-
vations reviewed here include the known persistence of B cells 
in the inflamed MS CNS of patients; the demonstration that 
CSF-derived B cell clones isolated from MS patients can bind 
CNS (including neurons and astrocytes) and cause complement-
mediated injury; the now recognized abnormal proinflammatory 
response propensity of MS B cells; potential cross-talk between 
B cells and activated CNS glial cells; and the reported association 
BOX 2 | The case of Neuromyelitis Optica (NMO).
For years, neuromyelitis optica (NMO) was largely considered a variant of 
MS until the discovery of serum antibodies to the water channel aquaporin 
(AQP)-4, which distinguished patients with NMO from those with MS (118, 
119). A growing range of clinical syndromes found to harbor such antibo-
dies has since lead to the characterization of “NMO spectrum disorders” 
(NMOSD) as a pathophysiologic spectrum that should be considered distinct 
from multiple sclerosis (120). Unlike MS (in which no particular antibody 
has been firmly linked to pathophysiology), a convergence of pathologic 
(121–125) and clinical (126–131) observations supports a pathophysiologic 
role of anti-AQP-4 antibodies in NMOSD [reviewed by Ref. (132, 133)]. While 
anti-AQP-4 antibodies are thought to be pathogenic in NMOSD, the obser-
vation that decreased NMO relapses seen following anti-CD20-mediated 
B-cell depletion do not correlate well with changes in anti-AQP4 antibody 
titers (134–136), indicates that the role of B cells in NMO may extend beyond 
antibody production. Such antibody-independent roles may include the 
capacity of B cells activate T cells and/or myeloid cells, as also implicated in 
MS. The observation that anti-AQP-4 antibodies are more readily detectable 
in serum rather than CSF of NMOSD patients has raised the question whe-
ther pathogenic antibodies are exclusively generated in the periphery and 
subsequently access the CNS, or whether plasmablasts and plasma cells 
that secrete such antibodies can be induced and fostered within the CNS. A 
recent study indicates that during NMO exacerbations, a substantial fraction 
of the intrathecal Ig proteome is generated by B cells of both peripheral and 
central origin (137). This suggests that in order for NMO therapies aiming 
to target the source of anti-AQP-4 antibodies to be most effective, they 
will need to access both the periphery and the CNS. Pathologically, NMO 
is characterized by an astrocytopathy with vasculocentric deposition of 
complement, vascular fibrosis, and eosinophilic infiltration, with associated 
white matter and gray matter injury. Meningeal immune cell collections with 
follicle-like features and cortical demyelination do not appear to be features 
of NMO pathology (138).
between B cell-containing meningeal immune cell infiltrates and 
presence of the subpial cortical injury increasingly thought to 
underlie progressive decline of functions in patients with pro-
gressive MS. Future work should aim to address key remaining 
questions (Box 1) thereby shedding light on which functionally 
distinct B cell subsets are present in the different anatomical 
subcompartments in the CNS, which molecular mechanisms 
and barriers are involved in their trafficking into those sites, 
what their antigenic specificities are, how are they fostered in 
the local environment, how they interact with glial and neural 
cells and ultimately how they contribute to disease propagation 
in the MS CNS as compared to the case of NMO (Box 2). These 
insights will hopefully help guide novel therapeutic options that 
may prove as useful for limiting progressive disease biology as 
peripheral B cell depletion has been for limiting relapses.
AUTHOR CONTRiBUTiONS
LM, HT, and AB-O designed and wrote the manuscript. AP, JG, 
and NP helped critically the manuscript.
FUNDiNG
Members of the “Canadian B cells in MS Team” (PIs: AB-O, AP, 
and JG) are funded through a collaborative team grant from the 
Research Foundation of the MS Society of Canada.
December 2015 | Volume 6 | Article 6369
Michel et al. B Cells in MS CNS
Frontiers in Immunology | www.frontiersin.org
ReFeReNCeS
1. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, 
Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the 
diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 
62(6):865–70.  doi:10.1001/archneur.62.6.865 
2. Tourtellotte WW, Ingram TJ, Shapshak P, Staugaitis SM, Reiber HO. 
Correlation of multiple sclerosis (MS) IgG fractionated by capillary isotacho-
phoresis (ITP) and by isoelectric focusing polyacrylamide gel electrophoresis 
(IEF-PAGE). Prog Clin Biol Res (1984) 146:379–84. 
3. Archelos JJ, Storch MK, Hartung HP. The role of B cells and auto-
antibodies in multiple sclerosis. Ann Neurol (2000) 47(6):694–706. 
doi:10.1002/1531-8249(200006)47:6<694::AID-ANA2>3.3.CO;2-N 
4. Trojano M, Logroscino GC, Pisicchio L, Rosato A, Bordo B, Citterio A, 
et  al. The multiple sclerosis cooperative etiological study in Italy: 
preliminary analysis of CSF findings. Ital J Neurol Sci (1987) Suppl 
6:71–6. 
5. Siritho S, Freedman MS. The prognostic significance of cerebrospinal fluid 
in multiple sclerosis. J Neurol Sci (2009) 279(1–2):21–5. doi:10.1016/j.
jns.2008.12.029 
6. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibod-
ies associated with myelin damage in multiple sclerosis. Nat Med (1999) 
5(2):170–5. doi:10.1038/5532 
7. Prineas JW, Raine CS. Electron microscopy and immunoperoxidase studies 
of early multiple sclerosis lesions. Neurology (1976) 26(6 Pt 2):29–32. 
doi:10.1212/WNL.26.6_Part_2.29 
8. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann 
H. Heterogeneity of multiple sclerosis lesions: implications for the 
pathogenesis of demyelination. Ann Neurol (2000) 47(6):707–17. 
doi:10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q 
9. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, 
et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl 
J Med (2011) 365(23):2188–97. doi:10.1056/NEJMoa1100648 
10. Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. 
Related B cell clones populate the meninges and parenchyma of patients  with 
multiple sclerosis. Brain (2011) 134(Pt 2):534–41. doi:10.1093/brain/awq350 
11. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et  al. 
Meningeal B-cell follicles in secondary progressive multiple sclerosis asso-
ciate with early onset of disease and severe cortical pathology. Brain (2007) 
130(Pt 4):1089–104. doi:10.1093/brain/awm038 
12. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of 
ectopic B-cell follicles with germinal centers in the meninges of patients with 
secondary progressive multiple sclerosis. Brain Pathol (2004) 14(2):164–74. 
doi:10.1111/j.1750-3639.2004.tb00049.x 
13. Stern JN, Yaari G, Vander Heiden JA, Church G, Donahue WF, Hintzen RQ, 
et al. B cells populating the multiple sclerosis brain mature in the draining 
cervical lymph nodes. Sci Transl Med (2014) 6(248):248ra107. doi:10.1126/
scitranslmed.3008879 
14. Palanichamy A, Apeltsin L, Kuo TC, Sirota M, Wang S, Pitts SJ, et  al. 
Immunoglobulin class-switched B cells form an active immune axis 
between CNS and periphery in multiple sclerosis. Sci Transl Med (2014) 
6(248):248ra106. doi:10.1126/scitranslmed.3008930 
15. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J. Clonal expansion 
and somatic hypermutation of V(H) genes of B cells from cerebrospinal 
fluid in multiple sclerosis. J Clin Invest (1998) 102(5):1045–50. doi:10.1172/
JCI3568 
16. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. 
B cell repertoire diversity and clonal expansion in multiple sclerosis brain 
lesions. J Immunol (1999) 163(9):5133–44. 
17. Colombo M, Dono M, Gazzola P, Roncella S, Valetto A, Chiorazzi N, et al. 
Accumulation of clonally related B lymphocytes in the cerebrospinal fluid 
of multiple sclerosis patients. J Immunol (2000) 164(5):2782–9. doi:10.4049/
jimmunol.164.5.2782 
18. von Büdingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, 
et  al. B cell exchange across the blood-brain barrier in multiple sclerosis. 
J Clin Invest (2012) 122(12):4533–43. doi:10.1172/JCI63842 
19. Blauth K, Soltys J, Matschulat A, Reiter CR, Ritchie A, Baird NL, et  al. 
Antibodies produced by clonally expanded plasma cells in multiple 
sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta 
Neuropathol (2015) 130(6):765–81. doi:10.1007/s00401-015-1500-6 
20. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, et al. 
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp 
Med (2007) 204(10):2363–72. doi:10.1084/jem.20071053 
21. Derfuss T, Parikh K, Velhin S, Braun M, Mathey E, Krumbholz M, et  al. 
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis 
patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U 
S A (2009) 106(20):8302–7. doi:10.1073/pnas.0901496106 
22. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, et  al. Lipid 
microarrays identify key mediators of autoimmune brain inflammation. Nat 
Med (2006) 12(1):138–43. doi:10.1038/nm1344 
23. Brennan KM, Galban-Horcajo F, Rinaldi S, O’Leary CP, Goodyear CS, Kalna 
G, et  al. Lipid arrays identify myelin-derived lipids and lipid complexes 
as prominent targets for oligoclonal band antibodies in multiple sclerosis. 
J Neuroimmunol (2011) 238(1–2):87–95. doi:10.1016/j.jneuroim.2011.08.002 
24. Ho PP, Kanter JL, Johnson AM, Srinagesh HK, Chang EJ, Purdy TM, 
et  al. Identification of naturally occurring fatty acids of the myelin sheath 
that resolve neuroinflammation. Sci Transl Med (2012) 4(137):137ra73. 
doi:10.1126/scitranslmed.3003831 
25. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in mul-
tiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 8(11):613–23. 
doi:10.1038/nrneurol.2012.203 
26. Ligocki AJ, Rivas JR, Rounds WH, Guzman AA, Li M, Spadaro M, et al. A 
distinct class of antibodies may be an indicator of gray matter autoimmunity 
in early and established relapsing remitting multiple sclerosis patients. ASN 
Neuro (2015) 7(5):1759091415609613. doi:10.1177/1759091415609613 
27. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Brück W, et  al. 
Identification of a pathogenic antibody response to native myelin oligoden-
drocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 
103(50):19057–62. doi:10.1073/pnas.0607242103 
28. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, 
et  al. Age-dependent B cell autoimmunity to a myelin surface antigen in 
pediatric multiple sclerosis. J Immunol (2009) 183(6):4067–76. doi:10.4049/
jimmunol.0801888 
29. Meinl E, Derfuss T, Krumbholz M, Pröbstel AK, Hohlfeld R. Humoral 
autoimmunity in multiple sclerosis. J Neurol Sci (2011) 306(1–2):180–2. 
doi:10.1016/j.jns.2010.08.009 
30. Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostásy K, Berger T, et al. 
Distinction and temporal stability of conformational epitopes on myelin 
oligodendrocyte glycoprotein recognized by patients with different inflam-
matory central nervous system diseases. J Immunol (2013) 191(7):3594–604. 
doi:10.4049/jimmunol.1301296 
31. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, et al. 
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl 
J Med (2012) 367(2):115–23. doi:10.1056/NEJMoa1110740 
32. Kraus V, Srivastava R, Kalluri SR, Seidel U, Schuelke M, Schimmel M, et al. 
Potassium channel KIR4.1-specific antibodies in children with acquired 
demyelinating CNS disease. Neurology (2014) 82(6):470–3. doi:10.1212/
WNL.0000000000000097 
33. Ketelslegers IA, Van Pelt DE, Bryde S, Neuteboom RF, Catsman-Berrevoets 
CE, Hamann D, et al. Anti-MOG antibodies plead against MS diagnosis in an 
acquired demyelinating syndromes cohort. Mult Scler (2015) 21(12):1513–20. 
doi:10.1177/1352458514566666 
34. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. 
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, 
phase I trial. Ann Neurol (2008) 63(3):395–400. doi:10.1002/ana.21363 
35. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell 
depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J 
Med (2008) 358(7):676–88. doi:10.1056/NEJMoa0706383 
36. Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, Barkhof F, et  al. 
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, 
placebo-controlled, multicentre trial. Lancet (2011) 378(9805):1779–87. 
doi:10.1016/S0140-6736(11)61649-8 
37. Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. 
Rituximab in patients with primary progressive multiple sclerosis: results of 
a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 
(2009) 66(4):460–71. doi:10.1002/ana.21867 
December 2015 | Volume 6 | Article 63610
Michel et al. B Cells in MS CNS
Frontiers in Immunology | www.frontiersin.org
38. Gwathmey K, Balogun RA, Burns T. Neurologic indications for therapeutic 
plasma exchange: 2013 update. J Clin Apher (2014) 29(4):211–9. doi:10.1002/
jca.21331 
39. Annunziata P, Giorgio A, De Santi L, Zipoli V, Portaccio E, Amato MP, 
et  al. Absence of cerebrospinal fluid oligoclonal bands is associated with 
delayed disability progression in relapsing-remitting MS patients treated 
with interferon-beta. J Neurol Sci (2006) 244(1–2):97–102. doi:10.1016/j.
jns.2006.01.004 
40. Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y, Robertson NP, Scolding 
NJ. CSF oligoclonal band status informs prognosis in multiple sclerosis: 
a case control study of 100 patients. J Neurol Neurosurg Psychiatry (2009) 
80(3):292–6. doi:10.1136/jnnp.2008.150896 
41. Villar LM, Masjuan J, González-Porqué P, Plaza J, Sádaba MC, Roldán E, et al. 
Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann 
Neurol (2003) 53(2):222–6. doi:10.1002/ana.10441 
42. Elliott C, Lindner M, Arthur A, Brennan K, Jarius S, Hussey J, et  al. 
Functional identification of pathogenic autoantibody responses in patients 
with multiple sclerosis. Brain (2012) 135(Pt 6):1819–33. doi:10.1093/brain/
aws105 
43. Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, 
et  al. Rituximab efficiently depletes increased CD20-expressing T cells in 
multiple sclerosis patients. J Immunol (2014) 193(2):580–6. doi:10.4049/
jimmunol.1400118 
44. O’Connor KC, Appel H, Bregoli L, Call ME, Catz I, Chan JA, et al. Antibodies 
from inflamed central nervous system tissue recognize myelin oligoden-
drocyte glycoprotein. J Immunol (2005) 175(3):1974–82. doi:10.4049/
jimmunol.175.3.1974 
45. Bar-Or A, Grove R, Austin D, Tolson JM, VanMeter SA, Lewis E, et al. A 
randomized, double-blind, placebo-controlled, parallel-group, dose-ranging 
study to investigate the safety and MRI efficacy of subcutaneous ofatumumab 
in subjects with relapsing-remitting multiple sclerosis (RRMS). Neurology 
(2014) 82(10):S23.006. 
46. Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, 
et  al. Safety and efficacy of ofatumumab in relapsing-remitting multiple 
sclerosis: a phase 2 study. Neurology (2014) 82(7):573–81. doi:10.1212/
WNL.0000000000000125 
47. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, et  al. 
Changes in B- and T-lymphocyte and chemokine levels with rituximab treat-
ment in multiple sclerosis. Arch Neurol (2010) 67(6):707–14. doi:10.1001/
archneurol.2010.99 
48. Pöllinger B, Krishnamoorthy G, Berer K, Lassmann H, Bösl MR, Dunn 
R, et  al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-
reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp 
Med (2009) 206(6):1303–16. doi:10.1084/jem.20090299 
49. Harp CT, Lovett-Racke AE, Racke MK, Frohman EM, Monson NL. Impact of 
myelin-specific antigen presenting B cells on T cell activation in multiple scle-
rosis. Clin Immunol (2008) 128(3):382–91. doi:10.1016/j.clim.2008.05.002 
50. Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, et al. 
Memory B cells from a subset of treatment-naive relapsing-remitting multiple 
sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma produc-
tion in response to myelin basic protein and myelin oligodendrocyte glyco-
protein. Eur J Immunol (2010) 40(10):2942–56. doi:10.1002/eji.201040516 
51. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector 
cytokines: a role in immune regulation? J Immunol (2004) 172(6):3422–7. 
doi:10.4049/jimmunol.172.6.3422 
52. Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, 
et al. Innate response activator B cells protect against microbial sepsis. Science 
(2012) 335(6068):597–601. doi:10.1126/science.1215173 
53. Dang VD, Hilgenberg E, Ries S, Shen P, Fillatreau S. From the regulatory 
functions of B cells to the identification of cytokine-producing plasma cell 
subsets. Curr Opin Immunol (2014) 28:77–83. doi:10.1016/j.coi.2014.02.009 
54. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell 
depletion therapy ameliorates autoimmune disease through ablation of 
IL-6-producing B cells. J Exp Med (2012) 209(5):1001–10. doi:10.1084/
jem.20111675 
55. Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, et al. * On behalf of 
the ‘Canadian B cells in MS Team’ proinflammatory GM-CSF producing B 
cells: implication in multiple sclerosis and B cell depletion therapy. Sci Transl 
Med (2015) 7(310):310ra166. doi:10.1126/scitranslmed.aab4176   
56. Shen P, Roch T, Lampropoulou V, O’Connor RA, Stervbo U, Hilgenberg 
E, et al. IL-35-producing B cells are critical regulators of immunity during 
autoimmune and infectious diseases. Nature (2014) 507(7492):366–70. 
doi:10.1038/nature12979 
57. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoim-
mune encephalomyelitis induction in genetically B cell-deficient mice. J Exp 
Med (1996) 184(6):2271–8. doi:10.1084/jem.184.6.2271 
58. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regu-
late autoimmunity by provision of IL-10. Nat Immunol (2002) 3(10):944–50. 
doi:10.1038/ni833 
59. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et  al. 
Distinct effector cytokine profiles of memory and naive human B cell subsets 
and implication in multiple sclerosis. J Immunol (2007) 178(10):6092–9. 
doi:10.4049/jimmunol.178.10.6092 
60. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et  al. 
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in 
MS? Ann Neurol (2010) 67(4):452–61. doi:10.1002/ana.21939 
61. Correale J, Farez M, Razzitte G. Helminth infections associated with mul-
tiple sclerosis induce regulatory B cells. Ann Neurol (2008) 64(2):187–99. 
doi:10.1002/ana.21438 
62. Michel L, Chesneau M, Manceau P, Genty A, Garcia A, Salou M, et al. Unaltered 
regulatory B-cell frequency and function in patients with multiple sclerosis. 
Clin Immunol (2014) 155(2):198–208. doi:10.1016/j.clim.2014.09.011 
63. Montalban X. Efficacy and Safety of Ocrelizumab in Primary Progressive 
Multiple Sclerosis-Results of the Placebo-Controlled, Double-Blind, Phase III 
ORATORIO Study. ECTRIMS Congress, Abstract 228 (2015).
64. Genentech Press Release (2015). Available from: http://www.gene.com/media/
press-releases/14608/2015-09-27/genentechs-ocrelizumab-first-investigation
65. Gonzalez M, Mackay F, Browning JL, Kosco-Vilbois MH, Noelle RJ. The 
sequential role of lymphotoxin and B cells in the development of splenic 
follicles. J Exp Med (1998) 187(7):997–1007. doi:10.1084/jem.187.7.997 
66. Tumanov AV, Kuprash DV, Mach JA, Nedospasov SA, Chervonsky AV. 
Lymphotoxin and TNF produced by B cells are dispensable for maintenance 
of the follicle-associated epithelium but are required for development of 
lymphoid follicles in the Peyer’s patches. J Immunol (2004) 173(1):86–91. 
doi:10.4049/jimmunol.173.1.86 
67. Cepok S, Jacobsen M, Schock S, Omer B, Jaekel S, Böddeker I, et al. Patterns 
of cerebrospinal fluid pathology correlate with disease progression in 
multiple sclerosis. Brain (2001) 124(Pt 11):2169–76. doi:10.1093/
brain/124.11.2169 
68. Cepok S, von Geldern G, Grummel V, Hochgesand S, Celik H, Hartung 
H, et  al. Accumulation of class switched IgD-IgM- memory B cells in the 
cerebrospinal fluid during neuroinflammation. J Neuroimmunol (2006) 
180(1–2):33–9. doi:10.1016/j.jneuroim.2006.06.031 
69. Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, et al. Short-lived 
plasma blasts are the main B cell effector subset during the course of multiple 
sclerosis. Brain (2005) 128(Pt 7):1667–76. doi:10.1093/brain/awh486 
70. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A, et  al. 
Recapitulation of B cell differentiation in the central nervous system of patients 
with multiple sclerosis. Proc Natl Acad Sci U S A (2004) 101(30):11064–9. 
doi:10.1073/pnas.0402455101 
71. Ritchie AM, Gilden DH, Williamson RA, Burgoon MP, Yu X, Helm K, et al. 
Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in 
the cerebrospinal fluid of patients with multiple sclerosis. J Immunol (2004) 
173(1):649–56. doi:10.4049/jimmunol.173.1.649 
72. Beltrán E, Obermeier B, Moser M, Coret F, Simó-Castelló M, Boscá I, 
et al. Intrathecal somatic hypermutation of IgM in multiple sclerosis and 
neuroinflammation. Brain (2014) 137(Pt 10):2703–14. doi:10.1093/brain/
awu205 
73. Obermeier B, Mentele R, Malotka J, Kellermann J, Kümpfel T, Wekerle H, 
et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes 
of cerebrospinal fluid in multiple sclerosis. Nat Med (2008) 14(6):688–93. 
doi:10.1038/nm1714 
74. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of 
multiple sclerosis: an overview. Brain Pathol (2007) 17(2):210–8. 
doi:10.1111/j.1750-3639.2007.00064.x 
75. Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and 
complement in postmortem multiple sclerosis tissue. Ann Neurol (2009) 
65(1):32–46. doi:10.1002/ana.21524 
December 2015 | Volume 6 | Article 63611
Michel et al. B Cells in MS CNS
Frontiers in Immunology | www.frontiersin.org
76. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: dis-
tribution of inflammatory cells in newly forming lesions. Ann Neurol (2009) 
66(6):739–53. doi:10.1002/ana.21800 
77. Obermeier B, Lovato L, Mentele R, Brück W, Forne I, Imhof A, et al. Related B 
cell clones that populate the CSF and CNS of patients with multiple sclerosis 
produce CSF immunoglobulin. J Neuroimmunol (2011) 233(1–2):245–8. 
doi:10.1016/j.jneuroim.2011.01.010 
78. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, et al. 
Meningeal inflammation plays a role in the pathology of primary progressive 
multiple sclerosis. Brain (2012) 135(Pt 10):2925–37. doi:10.1093/brain/
aws189 
79. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, 
et al. Meningeal inflammation is widespread and linked to cortical pathology in 
multiple sclerosis. Brain (2011) 134(Pt 9):2755–71. doi:10.1093/brain/awr182 
80. Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese IC, et al. Gadolinium-based 
MRI characterization of leptomeningeal inflammation in multiple sclerosis. 
Neurology (2015) 85(1):18–28. doi:10.1212/WNL.0000000000001587 
81. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, 
et al. A gradient of neuronal loss and meningeal inflammation in multiple 
sclerosis. Ann Neurol (2010) 68(4):477–93. doi:10.1002/ana.22230 
82. Kooi EJ, Geurts JJ, van Horssen J, Bø L, van der Valk P. Meningeal inflam-
mation is not associated with cortical demyelination in chronic multiple 
sclerosis. J Neuropathol Exp Neurol (2009) 68(9):1021–8. doi:10.1097/
NEN.0b013e3181b4bf8f 
83. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune 
privilege: hiding in plain sight. Immunol Rev (2006) 213:48–65. 
doi:10.1111/j.1600-065X.2006.00441.x 
84. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et  al. 
Structural and functional features of central nervous system lymphatic 
vessels. Nature (2015) 523(7560):337–41. doi:10.1038/nature14432 
85. Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, et al. 
A dural lymphatic vascular system that drains brain interstitial fluid and 
macromolecules. J Exp Med (2015) 212(7):991–9. doi:10.1084/jem.20142290 
86. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol 
(2015) 7(1):a020412. doi:10.1101/cshperspect.a020412 
87. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in 
endothelial cells. Nature (1987) 325(6101):253–7. doi:10.1038/325253a0 
88. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at 
the blood-brain barrier. Nat Rev Neurosci (2006) 7(1):41–53. doi:10.1038/
nrn1824 
89. Alvarez JI, Katayama T, Prat A. Glial influence on the blood brain barrier. Glia 
(2013) 61(12):1939–58. doi:10.1002/glia.22575 
90. Ransohoff RM, Schafer D, Vincent A, Blachère NE, Bar-Or A. 
Neuroinflammation: ways in which the immune system affects the brain. 
Neurotherapeutics (2015) 12(4):896–909. doi:10.1007/s13311-015-0385-3 
91. Decimo I, Fumagalli G, Berton V, Krampera M, Bifari F. Meninges: 
from protective membrane to stem cell niche. Am J Stem Cells (2012) 
1(2):92–105. 
92. Russi AE, Brown MA. The meninges: new therapeutic targets for multiple 
sclerosis. Transl Res (2015) 165(2):255–69. doi:10.1016/j.trsl.2014.08.005 
93. Wieseler-Frank J, Jekich BM, Mahoney JH, Bland ST, Maier SF, Watkins LR. 
A novel immune-to-CNS communication pathway: cells of the meninges 
surrounding the spinal cord CSF space produce proinflammatory cytokines 
in response to an inflammatory stimulus. Brain Behav Immun (2007) 
21(5):711–8. doi:10.1016/j.bbi.2006.07.004 
94. Bartholomäus I, Kawakami N, Odoardi F, Schläger C, Miljkovic D, Ellwart 
JW, et  al. Effector T cell interactions with meningeal vascular structures 
in nascent autoimmune CNS lesions. Nature (2009) 462(7269):94–8. 
doi:10.1038/nature08478 
95. Mues M, Bartholomäus I, Thestrup T, Griesbeck O, Wekerle H, Kawakami 
N, et al. Real-time in vivo analysis of T cell activation in the central nervous 
system using a genetically encoded calcium indicator. Nat Med (2013) 
19(6):778–83. doi:10.1038/nm.3180 
96. Allt G, Lawrenson JG. Is the pial microvessel a good model for blood-brain 
barrier studies? Brain Res Brain Res Rev (1997) 24(1):67–76. doi:10.1016/
S0165-0173(97)00011-8 
97. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking 
to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 
(2005) 26(9):485–95. doi:10.1016/j.it.2005.07.004 
98. Steffen BJ, Breier G, Butcher EC, Schulz M, Engelhardt B. ICAM-1, VCAM-1, 
and MAdCAM-1 are expressed on choroid plexus epithelium but not endo-
thelium and mediate binding of lymphocytes in vitro. Am J Pathol (1996) 
148(6):1819–38. 
99. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, et al. 
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS 
through the choroid plexus is required for the initiation of EAE. Nat Immunol 
(2009) 10(5):514–23. doi:10.1038/ni.1716 
100. Larochelle C, Cayrol R, Kebir H, Alvarez JI, Lécuyer MA, Ifergan I, et  al. 
Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes 
and promotes their recruitment to the central nervous system. Brain (2012) 
135(Pt 10):2906–24. doi:10.1093/brain/aws212 
101. Ifergan I, Kebir H, Terouz S, Alvarez JI, Lécuyer MA, Gendron S, et  al. 
Role of Ninjurin-1 in the migration of myeloid cells to central nervous 
system inflammatory lesions. Ann Neurol (2011) 70(5):751–63. doi:10.1002/
ana.22519 
102. Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonnière L, et al. 
Central nervous system recruitment of effector memory CD8+ T lympho-
cytes during neuroinflammation is dependent on alpha4 integrin. Brain 
(2011) 134(Pt 12):3560–77. doi:10.1093/brain/awr268 
103. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, 
et al. Activated leukocyte cell adhesion molecule promotes leukocyte traf-
ficking into the central nervous system. Nat Immunol (2008) 9(2):137–45. 
doi:10.1038/ni1551 
104. Ifergan I, Kébir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R, et al. 
The blood-brain barrier induces differentiation of migrating monocytes into 
Th17-polarizing dendritic cells. Brain (2008) 131(Pt 3):785–99. doi:10.1093/
brain/awm295 
105. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barri-
ers in multiple sclerosis. Biochim Biophys Acta (2011) 1812(2):252–64. 
doi:10.1016/j.bbadis.2010.06.017 
106. Alvarez JI, Kébir H, Cheslow L, Chabarati M, Larochelle C, Prat A. JAML 
mediates monocytes andCD8 T cell migration across the brain endothelium. 
Ann Clin Transl Neurol (2015) 2(11):1032–7. doi:10.1002/acn3.255 
107. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, et al. Natalizumab 
effects on immune cell responses in multiple sclerosis. Ann Neurol (2006) 
59(5):748–54. doi:10.1002/ana.20859 
108. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, et al. Determinants 
of human B cell migration across brain endothelial cells. J Immunol (2003) 
170(9):4497–505. doi:10.4049/jimmunol.170.9.4497 
109. Lehmann-Horn K, Sagan SA, Bernard CC, Sobel RA, Zamvil SS. B-cell very 
late antigen-4 deficiency reduces leukocyte recruitment and susceptibility 
to central nervous system autoimmunity. Ann Neurol (2015) 77(5):902–8. 
doi:10.1002/ana.24387 
110. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope 
spreading initiates in the CNS in two mouse models of multiple sclerosis. 
Nat Med (2005) 11(3):335–9. doi:10.1038/nm1202 
111. Quintana FJ, Patel B, Yeste A, Nyirenda M, Kenison J, Rahbari R, et  al. 
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. 
Neurology (2014) 83(24):2219–26. doi:10.1212/WNL.0000000000001066 
112. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progres-
sive multiple sclerosis. Lancet Neurol (2015) 14(2):183–93. doi:10.1016/
S1474-4422(14)70256-X 
113. Montesinos-Rongen M, Purschke FG, Brunn A, May C, Nordhoff E, 
Marcus  K, et  al. Primary central nervous system (CNS) lymphoma B cell 
receptors recognize CNS proteins. J Immunol (2015) 195(3):1312–9. 
doi:10.4049/jimmunol.1402341 
114. Ragheb S, Li Y, Simon K, VanHaerents S, Galimberti D, De Riz M, et  al. 
Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 
(2011) 17(7):819–29. doi:10.1177/1352458511398887 
115. Rentzos M, Cambouri C, Rombos A, Nikolaou C, Anagnostouli M, Tsoutsou 
A, et  al. IL-15 is elevated in serum and cerebrospinal fluid of patients 
with multiple sclerosis. J Neurol Sci (2006) 241(1–2):25–9. doi:10.1016/j.
jns.2005.10.003 
116. Uccelli A, Pedemonte E, Narciso E, Mancardi G. Biological markers 
of the inflammatory phase of multiple sclerosis. Neurol Sci (2003) 24 
(Suppl 5):S271–4. doi:10.1007/s10072-003-0172-5 
117. Matsumoto M, Baba A, Yokota T, Nishikawa H, Ohkawa Y, Kayama H, 
et  al. Interleukin-10-producing plasmablasts exert regulatory function in 
December 2015 | Volume 6 | Article 63612
Michel et al. B Cells in MS CNS
Frontiers in Immunology | www.frontiersin.org
autoimmune inflammation. Immunity (2014) 41(6):1040–51. doi:10.1016/j.
immuni.2014.10.016 
118. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara 
K, et al. A serum autoantibody marker of neuromyelitis optica: distinction 
from multiple sclerosis. Lancet (2004) 364(9451):2106–12. doi:10.1016/
S0140-6736(04)17551-X 
119. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of 
optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp 
Med (2005) 202(4):473–7. doi:10.1084/jem.20050304 
120. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis 
T, et  al. International consensus diagnostic criteria for neuromyelitis 
optica spectrum disorders. Neurology (2015) 85(2):177–89. doi:10.1212/
WNL.0000000000001729 
121. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff 
RM, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neu-
romyelitis optica. Brain (2002) 125(Pt 7):1450–61. doi:10.1093/brain/awf151 
122. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss 
of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple 
sclerosis. Brain (2007) 130(Pt 5):1224–34. doi:10.1093/brain/awm047 
123. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al. 
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuro-
myelitis optica from multiple sclerosis. Brain (2007) 130(Pt 5):1194–205. 
doi:10.1093/brain/awl371 
124. Sinclair C, Kirk J, Herron B, Fitzgerald U, McQuaid S. Absence of aquaporin-4 
expression in lesions of neuromyelitis optica but increased expression in mul-
tiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol 
(2007) 113(2):187–94. doi:10.1007/s00401-006-0169-2 
125. Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K, et al. 
Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specific-
ity, and direct comparison with immunohistochemistry. J Neurol Sci (2012) 
320(1–2):32–7. doi:10.1016/j.jns.2012.06.002 
126. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, 
et  al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive 
patients with neuromyelitis optica. Mult Scler (2007) 13(1):128–32. 
doi:10.1177/1352458506071174 
127. Merle H, Olindo S, Jeannin S, Valentino R, Mehdaoui H, Cabot F, et  al. 
Treatment of optic neuritis by plasma exchange (add-on) in neuro-
myelitis optica. Arch Ophthalmol (2012) 130(7):858–62. doi:10.1001/
archophthalmol.2012.1126 
128. Khatri BO, Kramer J, Dukic M, Palencia M, Verre W. Maintenance plasma 
exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apher 
(2012) 27(4):183–92. doi:10.1002/jca.21215 
129. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma 
exchange in severe spinal attacks associated with neuromyelitis optica spectrum 
disorder. Mult Scler (2009) 15(4):487–92. doi:10.1177/1352458508100837 
130. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab 
treatment in patients with neuromyelitis optica spectrum disorder. JAMA 
Neurol (2013) 70(9):1110–7. doi:10.1001/jamaneurol.2013.3071 
131. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. 
Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. 
Ann Neurol (2015). doi:10.1002/ana.24554 
132. Bennett JL, O’Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, et al. 
B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 
(2015) 2(3):e104. doi:10.1212/NXI.0000000000000104 
133. Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber MS, 
et  al. Immunopathogenesis of neuromyelitis optica. Adv Immunol (2014) 
121:213–42. doi:10.1016/B978-0-12-800100-4.00006-4 
134. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label 
study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 
64(7):1270–2. doi:10.1212/01.WNL.0000159399.81861.D5 
135. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. 
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 
25 patients. Arch Neurol (2008) 65(11):1443–8. doi:10.1001/archneur.65.11.
noc80069 
136. Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, et al. Update 
on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 
(2015) 2(4):e134. doi:10.1212/NXI.0000000000000134 
137. Kowarik MC, Dzieciatkowska M, Wemlinger S, Ritchie AM, Hemmer B, 
Owens GP, et  al. The cerebrospinal fluid immunoglobulin transcriptome 
and proteome in neuromyelitis optica reveals central nervous system-spe-
cific B cell populations. J Neuroinflammation (2015) 12:19. doi:10.1186/
s12974-015-0240-9 
138. Popescu BF, Parisi JE, Cabrera-Gómez JA, Newell K, Mandler RN, Pittock SJ, 
et al. Absence of cortical demyelination in neuromyelitis optica. Neurology 
(2010) 75(23):2103–9. doi:10.1212/WNL.0b013e318200d80c 
Conflict of Interest Statement: Laure Michel, Hanane Touil, Natalia B. Pikor, 
Jennifer L. Gommerman, and Alexandre Prat have no conflicts of interest. Amit 
Bar-Or has participated as a speaker in meetings sponsored by and received 
consulting fees and/or grant support from Biogen Idec, Diogenix, Genentech, 
Sanofi-Genzyme, GlaxoSmithKline, Novartis, Ono Pharma, Teva Neuroscience, 
Receptos Inc., Roche, and Merck/EMD Serono.
Copyright © 2015 Michel, Touil, Pikor, Gommerman, Prat and Bar-Or. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
